Valneva seeking partner for $350M Lyme disease vaccine effort, prepping for phase 2

**Comment after article**
If you haven’t read Weintrub’s book, do. It’s quite an eye-opener and still highly relevant today even though it was written in 2008. But, a lot has happened since both the 1998 Lyme vaccine and Weintraub’s 2008 book that declares the Lyme vaccine caused “rare” adverse events. THIS VACCINE CAUSED 229 DEATHS, INCLUDING 43 SUICIDES  Did you know that the LYMERIX vaccine caused 640 emergency room visits, 34 life threatening reactions, 77 hospitalizations, 198 disabilities, and 6 deaths? In a vile cesspool of conflicts of interest are university patent holders, drug companies, and the FDA itself as another patent holder. It generated 40 million dollars before it was yanked. (2008, Drymon)
As you can see in Dr. Lapenta’s article, the death toll raised to 229. Besides, death and suicide, please see: One doctor stated that 21 patients developed severe arthritis after receiving the LYMERIX vaccine. “Given that Dr. Marks lead the clinical trials for Lymerix’s competitor, the OspA vaccine produced and then abandoned by Aventis Pasteur, his conclusions mean a lot. “In my opinion,” he told FDA officials, “there is sufficient evidence that Lymerix is causally related to severe rheumatologic, neurologic, autoimmune, and other adverse events in some individuals. This evidence is such as to warrant a significantly heightened degree of warnings and possible limitations or removal from marketing of Lymerix.”

Dr. Stricker states:
Another Lyme OspA Vaccine Whitewash
The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccines.
Weintraub’s article states that when considering vaccines one has to weigh the risk of the vaccine against the possible adverse reactions – which is true; however, we need to first start with being honest about the number of people with adverse reactions. In doing this, two things are important to keep in mind: 1) All numbers on ALL issues regarding Lyme/MSIDS are notoriously low. 2) ALL numbers on ALL issues regarding vaccines are notoriously low and downplayed.

Since 2008, more has come out about the ability of vaccines to reactivate latent infections:
This is an extremely important point to acknowledge as mainstream medicine STILL hasn’t even accepted the fact Lyme/MSIDS patients are often infected with far more than Lyme (Borrelia) to begin with. The current news that vaccines can activate even latent infections muddies and troubles the waters further and frankly spells doom to Lyme/MSIDS patients.

Personally, every single Lyme/MSIDS patient I know who has undergone vaccination has relapsed. That’s kind of a big deal.

This issue of problems with vaccines has exploded in recent years with new discoveries of contamination:
This contamination could very well be contributing to disease epidemics, including Lyme/MSIDS:
The first-ever study involving a truly unvaccinated population suggests that: fully vaccinated children may be trading the prevention of certain acute illnesses (chicken pox, pertussis) for more chronic illnesses and neurodevelopmental disorders like ADHD and Autism. The scientists also found that children born prematurely, who were vaccinated, were 6.6 times more likely to have a neurodevelopmental disorder.
The involvement of heavy metals in vaccines:
Lyme/MSIDS patients are finding that similarly to autistic children, they improve once they have chelated for heavy metals. Where are these metals coming from?